Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Dalhoff

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
The Lancet. Infectious Diseases|June 5, 2003
Immunomodulatory effects of quinolonesAxel Dalhoff, Itamar Shalit
Antimicrobial Agents and Chemotherapy|October 17, 2012
Activity of moxifloxacin, imipenem, and ertapenem against Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, and Bacteroides fragilis in monocultures and mixed cultures in an in vitro pharmacokinetic/pharmacodynamic model simulating concentrations in the human pancreasSabine Schubert, Axel Dalhoff
The Journal of Antimicrobial Chemotherapy|May 1, 2004
Towards targeted prescribing: will the cure for antimicrobial resistance be specific, directed therapy through improved diagnostic testing?Lance R Peterson, Axel Dalhoff
Chemotherapy|June 20, 2003
The art of fusion: from penams and cephems to penemsAxel Dalhoff, Christopher J Thomson
Antimicrobial Agents and Chemotherapy|January 20, 2011
Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urineAxel Dalhoff, Will Stubbings, Sabine Schubert
International Journal of Antimicrobial Agents|September 23, 2019
Comparative evaluation of eight in vitro pharmacodynamic models of infection: Activity of moxifloxacin against Escherichia coli and Streptococcus pneumoniae as an exemplary exampleAxel Dalhoff, Karen Bowker, Alasdair MacGowan
Biochemical Pharmacology|January 18, 2006
Redefining penemsAxel Dalhoff, Nebojsa Janjic, Roger Echols
International Journal of Antimicrobial Agents|October 7, 2008
Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study)Enno Jacobs, Axel Dalhoff, Gisela Korfmann
Antimicrobial Agents and Chemotherapy|May 29, 2014
Alternative strategies for proof-of-principle studies of antibacterial agentsAxel Dalhoff, Andrej Weintraub, Carl Erik Nord
Antimicrobial Agents and Chemotherapy|January 18, 2018
Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized IsolatesAndreas Vente, Christine Bentley, Mark Lückermann, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
The Lancet. Infectious Diseases|June 5, 2003
Immunomodulatory effects of quinolonesAxel Dalhoff, Itamar Shalit
Antimicrobial Agents and Chemotherapy|October 17, 2012
Activity of moxifloxacin, imipenem, and ertapenem against Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, and Bacteroides fragilis in monocultures and mixed cultures in an in vitro pharmacokinetic/pharmacodynamic model simulating concentrations in the human pancreasSabine Schubert, Axel Dalhoff
The Journal of Antimicrobial Chemotherapy|May 1, 2004
Towards targeted prescribing: will the cure for antimicrobial resistance be specific, directed therapy through improved diagnostic testing?Lance R Peterson, Axel Dalhoff
Chemotherapy|June 20, 2003
The art of fusion: from penams and cephems to penemsAxel Dalhoff, Christopher J Thomson
Antimicrobial Agents and Chemotherapy|January 20, 2011
Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urineAxel Dalhoff, Will Stubbings, Sabine Schubert
International Journal of Antimicrobial Agents|September 23, 2019
Comparative evaluation of eight in vitro pharmacodynamic models of infection: Activity of moxifloxacin against Escherichia coli and Streptococcus pneumoniae as an exemplary exampleAxel Dalhoff, Karen Bowker, Alasdair MacGowan
Biochemical Pharmacology|January 18, 2006
Redefining penemsAxel Dalhoff, Nebojsa Janjic, Roger Echols
International Journal of Antimicrobial Agents|October 7, 2008
Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study)Enno Jacobs, Axel Dalhoff, Gisela Korfmann
Antimicrobial Agents and Chemotherapy|May 29, 2014
Alternative strategies for proof-of-principle studies of antibacterial agentsAxel Dalhoff, Andrej Weintraub, Carl Erik Nord
Antimicrobial Agents and Chemotherapy|January 18, 2018
Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized IsolatesAndreas Vente, Christine Bentley, Mark Lückermann, et al.
Pageof 3